---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-23-002136"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2023-06-05T23:59:59+00:00"
generated_at: "2026-06-14T07:20:21.699738+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Chemomab appoints Adi Mor CEO, Sigal Fattal CFO; extends cash runway to end of 2024

## Summary
- Adi Mor, co-founder and CSO, reappointed CEO effective June 1, 2023, replacing Dale Pfost.
- Sigal Fattal, VP Finance, reappointed CFO, replacing Donald Marvin, effective same date.
- Nissim Darvish appointed Chairman of Board, replacing Pfost.
- Cash runway extended to end of 2024 via cost reductions; Phase 2 SSc trial suspended to preserve capital.
- On track for PSC Phase 2 topline data readout in latter part of 2024.

## SEC filing metadata
- accession: 0001178913-23-002136
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2023-06-05T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891323002136/0001178913-23-002136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891323002136/zk2329839.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-23-002136
- JSON: https://secwatch.observer/filing/0001178913-23-002136.json
- Plain text: https://secwatch.observer/filing/0001178913-23-002136.txt

## Key facts
- Executive change
  Dale Pfost departed as Chief Executive Officer at Chemomab Therapeutics Ltd..
  - Action: stepped down
  - Role: Chief Executive Officer
  source text: In connection with his replacement as Chief Executive Officer, on June 1, 2023, Dr. Dale Pfost agreed to step down from his position on the Board, including in his capacity as Chairman of the Board, effective as of the same date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534248/000117891323002136/0001178913-23-002136-index.htm
- Executive change
  Adi Mor was appointed as Chief Executive Officer at Chemomab Therapeutics Ltd..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: appointed Dr. Adi Mor, co-founder of the Company, a current class III member of the Board and the Company's Chief Scientific Officer, as Chief Executive Officer of the Company to replace Dr. Dale Pfost, effective as of the same date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534248/000117891323002136/0001178913-23-002136-index.htm
- Executive change
  Sigal Fattal was appointed as Chief Financial Officer at Chemomab Therapeutics Ltd..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: the Board appointed Ms. Sigal Fattal, the VP of Finance of the Company, as the Chief Financial Officer of the Company to replace Mr. Donald Marvin, effective as of the same date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534248/000117891323002136/0001178913-23-002136-index.htm
- Executive change
  Donald Marvin resigned as Chief Financial Officer at Chemomab Therapeutics Ltd..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: the Board appointed Ms. Sigal Fattal, the VP of Finance of the Company, as the Chief Financial Officer of the Company to replace Mr. Donald Marvin, effective as of the same date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534248/000117891323002136/0001178913-23-002136-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.